Beyond CRISPR: The Emerging Frontier of Human Mitochondrial DNA Editing

 

Why Mitochondrial DNA Matters

Mitochondria are the energy-producing organelles of human cells. Unlike most cellular structures, mitochondria possess their own small genome known as mitochondrial DNA (mtDNA). The human mitochondrial genome is only about 16.5 kilobases long, yet it encodes 13 essential proteins of the respiratory chain, 22 transfer RNAs, and two ribosomal RNAs required for mitochondrial protein synthesis.

Because the mitochondrial genome is extremely compact and functionally dense, even a single mutation can severely impair cellular energy production. Defects in mtDNA are associated with a wide spectrum of disorders, including neurodegenerative diseases, cancer, diabetes, autoimmune disorders, ageing-related decline, and inherited mitochondrial diseases.

One important example is Leber’s hereditary optic neuropathy (LHON), a mitochondrial disease that causes sudden central vision loss, often in young adults. The most common LHON mutation, 11778G>A, occurs in the mitochondrial ND4 gene, a key component of the respiratory chain. This mutation changes the ND4 protein structure and disrupts mitochondrial ATP production, particularly affecting retinal nerve cells that require large amounts of energy.

Despite decades of research, effective treatments for mitochondrial diseases remain limited. One rare example is idebenone, a coenzyme Q analogue approved in Europe for early-stage LHON, but its benefits are modest and only observed in some patients.

The development of technologies capable of directly editing mitochondrial DNA therefore represents one of the major goals of modern biomedical science.

Early Mitochondrial Gene Editing Technologies

Recent advances in genome editing have transformed nuclear genetics, but editing mtDNA has remained far more difficult. Classical CRISPR-Cas systems depend on guide RNAs, yet mitochondria import RNA inefficiently, creating a major barrier for CRISPR-based mitochondrial editing.

Researchers therefore developed alternative approaches based on DNA deaminases. The DdCBE system enabled conversion of C base pairs into T pairs in mammalian mtDNA. Later, TALED systems enabled A to G conversions.

These were historic breakthroughs because they allowed direct editing of mammalian mitochondrial genomes for the first time. However, these technologies have important limitations. They can perform only “transition” mutations — replacing one purine with another purine or one pyrimidine with another pyrimidine. They cannot efficiently create transversions, insertions, deletions, inversions, or larger DNA modifications. In addition, these methods may generate off-target and bystander edits.

As a result, many pathogenic mitochondrial mutations still cannot be corrected using current editing technologies.

The Challenge of Editing Mitochondrial DNA

Editing mtDNA presents unique biological challenges. Mammalian mitochondria lack the classical non-homologous end joining (NHEJ) pathway used by the nucleus to repair DNA breaks. Instead, linearized mitochondrial DNA is often rapidly degraded.

However, researchers discovered that mitochondria possess another DNA repair mechanism called microhomology-mediated end joining (MMEJ), as well as homologous recombination activities. These pathways may potentially be exploited for mitochondrial genome engineering.

The central objective of this study was therefore to determine whether mitochondrial MMEJ machinery could be harnessed to perform site-directed mutagenesis of human mtDNA.

Unlike deaminase-based systems, an MMEJ-driven strategy could theoretically introduce virtually any type of nucleotide modification, including multiple mutations, insertions, or deletions.

Demonstration of MMEJ Activity in Human Mitochondria

To test whether human mitochondria possess functional MMEJ activity, researchers synthesized DNA duplexes containing matching microhomology sequences and incubated them with mitochondrial extracts from HEK293T cells.

Successful joining of DNA fragments through these homologous regions would indicate active MMEJ repair.

The experiments demonstrated clear MMEJ activity in mitochondrial extracts, while classical NHEJ activity was absent. In contrast, nuclear extracts showed both MMEJ and NHEJ repair.

Importantly, the microhomology regions were designed to correspond to the mitochondrial ND4 site involved in LHON, demonstrating that disease-relevant mtDNA loci could participate in MMEJ-mediated recombination.

Additional experiments using engineered DNA fragments confirmed that mitochondria could successfully recombine donor DNA molecules and introduce new DNA sequences at targeted sites.

These findings established that human mitochondria naturally possess repair machinery potentially suitable for genome editing.

RNA Mitochondrial Import Signals (RMIS): Delivering DNA into Mitochondria

One of the greatest obstacles in mitochondrial genome engineering is transporting donor DNA into mitochondria inside living cells.

The researchers addressed this challenge using RNA mitochondrial import signals (RMIS), specialized RNA hairpin structures previously discovered to facilitate RNA import into mitochondria.

The RMIS used in this study was derived from the D-arm of yeast tRNALys. Researchers fused this RNA structure to donor DNA molecules designed to target the ND4 gene.

Remarkably, the experiments demonstrated that relatively large 49-nucleotide double-stranded DNA molecules could successfully enter human mitochondria.

To confirm true mitochondrial delivery, purified mitochondria and mitoplasts were treated with nucleases to destroy external nucleic acids. DNA protected from nuclease digestion was therefore localized inside the mitochondrial matrix.

Even more remarkably, when only one strand of the DNA duplex carried the RMIS signal, the entire duplex still entered mitochondria. This suggested that double-stranded DNA could cross mitochondrial membranes intact.

These findings substantially expanded understanding of mitochondrial nucleic acid transport and opened new possibilities for mitochondrial gene therapy.

Mitochondrial Genome Editing by Donor DNA Delivery

The researchers next investigated whether imported donor DNA could directly modify mitochondrial genomic sequences.

Human HEK293T cells were transfected with donor single-stranded and double-stranded DNA molecules targeting the ND4 gene. After several days, mitochondrial DNA was isolated and subjected to deep sequencing.

The scientists detected statistically significant introduction of the designed four-nucleotide modification into mitochondrial DNA.

Although the editing efficiency was low — approximately 0.021% to 0.042% — this represented the first demonstration that donor DNA delivery could induce predefined multi-nucleotide edits in human mtDNA.

Importantly, double-stranded donor DNA performed substantially better than single-stranded DNA.

This result was highly significant because current deaminase-based mitochondrial editing technologies cannot generate such four-nucleotide modifications.

Combining Donor DNA with CRISPR-Based Mitochondrial Cleavage

To improve editing efficiency, researchers attempted to combine donor DNA delivery with mitochondrial DNA cleavage using mito-AsCas12a, a mitochondria-targeted CRISPR nuclease.

The strategy was based on the idea that site-specific cleavage might stimulate mitochondrial repair pathways and facilitate donor DNA integration.

New donor DNA molecules were designed to introduce silent mutations that would prevent re-cleavage by the CRISPR system after successful editing.

Researchers also reduced levels of MGME1, a mitochondrial exonuclease involved in degradation of linearized mtDNA, hoping this would stabilize broken DNA ends and improve recombination efficiency.

Although the intended five-nucleotide edits were detected, overall editing efficiency was unexpectedly extremely low.

Several factors may explain this outcome, including poor mitochondrial cleavage efficiency, impaired mitochondrial function of the experimental cell line, and broader distribution of engineered mutations across the target region.

Nevertheless, the experiments provided important proof-of-concept evidence that CRISPR-assisted mitochondrial genome editing may eventually become feasible.

Proposed Mechanism of MMEJ-Based Mitochondrial Editing

The researchers proposed a mechanistic model for donor DNA-mediated mtDNA editing.

According to this model, naturally occurring mitochondrial DNA breaks — generated by reactive oxygen species or replication stress — create opportunities for donor DNA integration through MMEJ.

Mitochondrial nucleases such as EndoG and ExoG may first process the imported donor DNA molecules.

Subsequently, DNA repair proteins including PARP1, MRE11, BRCA1, RAD51, POLQ, FEN1, and DNA ligase III may facilitate strand invasion, microhomology alignment, DNA synthesis, and end joining.

Double-stranded donor DNA likely performs better because its free ends mimic DNA double-strand breaks and more effectively recruit repair machinery.

This proposed mechanism represents one of the first detailed molecular models for programmable mitochondrial genome editing in human cells.

Future Perspectives and Clinical Potential

Although editing efficiencies remain extremely low, this study represents a major conceptual advance in mitochondrial biology.

Current mitochondrial therapies mainly rely on heteroplasmy shifting — selectively eliminating mutant mtDNA molecules to increase the proportion of healthy genomes. However, this approach may not work for nearly homoplasmic diseases such as LHON, where most mitochondrial genomes already carry the mutation.

The RMIS-MMEJ strategy described here could potentially overcome this limitation because it aims to directly rewrite mitochondrial DNA sequences.

Importantly, this method may theoretically enable not only point mutations but also larger deletions, insertions, and complex genomic modifications.

Further optimization of donor DNA design, mitochondrial delivery systems, CRISPR targeting, and mitochondrial repair pathway manipulation could eventually transform this early proof-of-concept into a clinically useful technology.

Conclusion

This study introduces a novel strategy for editing human mitochondrial DNA by combining RNA mitochondrial import signals with the intrinsic microhomology-mediated end joining machinery of mitochondria.

The researchers demonstrated that double-stranded donor DNA can be imported into human mitochondria and can introduce predefined multi-nucleotide changes into the mitochondrial genome.

Although the efficiency remains low, the work represents one of the first demonstrations of programmable donor DNA-mediated mitochondrial genome editing in living human cells.

Most importantly, unlike existing deaminase-based technologies limited to transition mutations, this approach has the theoretical potential to introduce virtually any type of genetic modification into mammalian mtDNA.

These findings mark an important step toward future gene therapies for mitochondrial diseases, neurodegeneration, ageing-related disorders, and other conditions linked to mitochondrial dysfunction.

Reference

Vadim V.M., et al. Mitochondrial genome microhomology-mediated editing by donor DNA delivery into mitochondria in human cells. Molecular Therapy Nucleic Acids, 2026,102959, https://doi.org/10.1016/j.omtn.2026.102959.

Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI) or Google Gemini.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)